Aims: The CHA 2 DS 2 VASc score is used to evaluate the risk of thromboembolic events in patients with non-valvular atrial fibrillation. We assessed the prognostic yield of CHA 2 DS 2 VASc for new-onset atrial fibrillation, cardiovascular morbidity and mortality in a non-atrial fibrillation population. Methods: We analysed a population-based cohort of 22,179 middle-aged individuals with (n ¼ 3542) and without (n ¼ 18,367) a history of atrial fibrillation; we grouped the population into five CHA 2 DS 2 VASc strata (0-1-2-3-!4), and compared the risk of major adverse cerebro-cardiovascular events and mortality. Furthermore, we analysed the annual incidence of atrial fibrillation across different CHA 2 DS 2 VASc strata. Results: Over a median follow-up of 15 years, 1572 patients (6.9%) had ischaemic strokes, 2162 (9.5%) coronary events and 5899 (26%) died. The cumulative incidence of ischaemic stroke in CHA 2 DS 2 VASc ! 4 subjects without atrial fibrillation was similar to patients with atrial fibrillation and CHA 2 DS 2 VASc 2, with a 10-year crude incidence rate of 0.91 (95% confidence interval (CI) 0.68-1.19) and 1.13 (95% CI 0.93-1.36) ischaemic strokes per 100 patient-years, respectively. CHA 2 DS 2 VASc in a non-atrial fibrillation population showed higher predictive accuracy for ischaemic stroke compared with an atrial fibrillation population (area under the curve 0.60 vs. 0.56; P ¼ 0.001). In multivariable Cox regression analysis, CHA 2 DS 2 VASc ! 2 was an independent predictor of all-cause death (adjusted hazard ratio (aHR) 2.58; 95% CI 2.42-2.76), cardiovascular death (aHR 3.40; 95% CI 2.98-3.89), ischaemic stroke (aHR 2.20; 95% CI 1.92-2.53) and coronary events (aHR 1.83; 95% CI 1.63-2.04). The cumulative incidence of atrial fibrillation was greater with increasing CHA 2 DS 2 VASc strata, with an absolute annual incidence of more than 2% per year if CHA 2 DS 2 VASc ! 4. Conclusion: The CHA 2 DS 2 VASc score is a sensitive tool for predicting new-onset atrial fibrillation and adverse outcomes in subjects both with and without atrial fibrillation.
Introduction
The CHA 2 DS 2 VASc score (congestive heart failure, hypertension, age ! 75 years [doubled] , diabetes, stroke/transient ischaemic attack/thromboembolism [doubled] , vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-74 years, sex category [female]), is used to evaluate the risk of thromboembolic events in patients with non-valvular atrial fibrillation (AF), and is recommended by current guidelines to guide the management of antithrombotic therapy. 1, 2 Most of the individual components of the CHA 2 DS 2 VASc score have been considered as risk factors for stroke, irrespective of the presence of AF, and are also included in older stroke risk assessment models, such as the Framingham risk score; 3 furthermore, they have been considered as cardiovascular risk factors in other risk assessment tools that focus on the prediction of overall cardiovascular risk. 4 Many components of the CHA 2 DS 2 VASc score have also been shown to predict outcome after stroke. In particular, heart failure (HF), hypertension, age, diabetes and previous stroke have been related to worse outcome in patients with acute stroke, irrespective of the presence of AF. [5] [6] [7] In recent years, the CHA 2 DS 2 VASc score has therefore been proposed to predict cardiovascular outcomes in clinical settings different from known AF. The score has indeed been related to subsequent all-cause mortality, 8 recurrent stroke, cardiovascular events and total mortality 9 in stroke patients; with subsequent stroke and death after an acute coronary event 10 or after coronary artery bypass grafting; 11 with subsequent ischaemic stroke, thromboembolism and death in HF; 12 and with subsequent stroke in a population free from AF burden. 13 Since the CHA 2 DS 2 VASc score is user-friendly and easy to apply, it might be useful for prospective risk assessment of major adverse cardio-and cerebro-vascular events (MACCEs) in the non-AF population, possibly guiding therapeutic decisions. Moreover, as many of the individual risk factors included in this score are also risk factors for AF itself, it might serve as a screening tool for the identification of patients at higher risk of newonset AF.
Accordingly, we hypothesised that the CHA 2 DS 2 VASc score may be independently associated with MACCEs and mortality in an AF-free population; and patients without AF but with a high CHA 2 DS 2 VASc score may have a risk of ischaemic stroke reaching/crossing the threshold for anticoagulation. Finally, we sought to assess the performance of the CHA 2 DS 2 VASc score in predicting new-onset AF in subjects without a pre-existing diagnosis of AF.
Materials and methods

Study cohort
The Malmo¨Diet and Cancer Study is a prospective cohort study in which all men born between 1923 and 1945 and women born between 1923 and 1950 from the city of Malmo¨, Sweden (total population 330,000) were invited to participate. The participation rate was approximately 40%. Men and women, totalling 30,447 participants, underwent a baseline examination between 1991 and 1996. Of these, 22,369 underwent a 5-year rescreening based on a follow-up questionnaire in 1997-2001. The average follow-up time from the rescreening was 15 AE 4 years (Supplementary Figure  1) . A full description of recruitment and screening procedures have been provided elsewhere. 14 The study complied with the Declaration of Helsinki, all individuals provided written informed consent and the protocol was approved by the regional ethics committee.
Definition of clinical characteristics
The participants underwent measurement of body weight and height, blood pressure (BP), and filled in a questionnaire on health, lifestyle, socioeconomic factors and medications at the baseline examination. Body surface area was calculated using the DuBois formula. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters (kg/m 2 ). A baseline questionnaire recorded the smoking status. 15 Hypertension was defined as systolic BP of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater or the use of antihypertensive medications. Diabetes was defined as self-reported, physician diagnosis of diabetes or the use of anti-diabetic medications. A history of AF, HF, stroke and vascular disease (previous myocardial infarction, any myocardial revascularisation, and/or peripheral artery disease) were defined as self-reported, physician diagnosis or based upon case retrieval from the Swedish National Hospital Discharge Register (SNHDR).
The CHA 2 DS 2 VASc score has been calculated based on the presence of its components retrieved both at baseline and at 5-year rescreening in order to provide the most updated baseline CHA 2 DS 2 VASc score and to validate the score itself by confirming the stability of potentially modifiable risk factors such as hypertension.
Ascertainment of clinical endpoints
All study participants were followed up to 31 December 2014 by linking a unique 10-digit personal identification number with the SNHDR, Swedish National Cause of Death Register (SNCDR) and Stroke Register of Malmo¨(STROMA). Diagnoses in the SNHDR are coded as primary or contributory and in the SNCDR as underlying or contributory cause of death, both using the International Classification of Diseases (ICD). The 9th edition (ICD-9) was used between 1987 and 1996 and the 10th edition (ICD-10) from 1997 until the present. Event-free subjects (n ¼ 116; 0.5%) who emigrated from Sweden before 31 December 2014 were assigned the date of emigration as the last follow-up date. A first diagnosis of AF or atrial flutter was ascertained by linkage of Swedish personal identification numbers to SNHDR and SDCDR using diagnosis codes 427D for ICD-9 and I48 for ICD-10. As in previous studies, 16, 17 the outcome of AF was defined as either a diagnosis of AF or atrial flutter, given the close interrelationship of these diseases. Subjects with a hospital discharge diagnosis of HF (427.00, 427.10, 428 [ICD-9] and I50 [ICD-10]) were considered to have HF if the diagnosis was listed as the primary diagnosis.
Furthermore, we analysed the following outcomes: all-cause mortality, cardiovascular death, any stroke, ischaemic stroke and coronary event. Stroke was defined according to the ICD-9 and ICD-10 systems as cases coded 430, 431, 434 and 436 or I60, I61, I63 and I64, respectively. STROMA was used for case retrieval. In addition, SNHDR and SNCDR were used for the retrieval of patients who moved out of Malmo¨. Ischaemic stroke was ascertained by ICD9-434 and ICD10-I63 codes. Coronary event was defined as fatal or non-fatal myocardial infarction or death due to coronary heart disease according to ICD9-410 and ICD10-I21 codes in SNHDR, and codes 410, 412 and 414 (ICD-9) or I21-I23 and I25 (ICD-10) in SNCDR. The register-based diagnosis of stroke and coronary event in STROMA and SNHDR have been found to be highly valid. 18 
Statistical analysis
The baseline characteristics of the study population at the time of the 1997-2001 rescreening were described using means (standard deviations [SD]) for continuous measures and number (percentage) for categorical measures. For the purpose of our analysis, we defined the AF population as subjects with prevalent and/or incident AF cases, and the non-AF population as subjects who never experienced AF from baseline until the end of the follow-up. We used the unpaired Student's t test to compare AF (prevalent or incident) versus non-AF groups for continuous variables and Fisher's exact test for categorical variables. We calculated crude incidence rates of all end points stratified by the presence of AF. Ninety-five per cent confidence intervals (CIs) of the crude incidence rates were estimated with the exact method of Poisson distribution. We performed time-toevent analyses by the Kaplan-Meier estimator and Bonferroni corrected log-rank test. We computed the absolute risks of all end points while accounting for competing risk of death using the method recommended by Gray. 19 Relative risks according to the CHA 2 DS 2 VASc score were estimated using the Jackknife pseudo values modelled in the generalised estimating equation to account for the competing risk of death. 20, 21 The pseudo values of each individual for the outcome of interest were obtained by the difference between the overall cumulative incidence and the leaveone-out (Jackknife) cumulative incidence. The pseudo values were then regressed onto the CHA 2 DS 2 VASc score in a generalised estimating equation using a loglink function and the resultant regression coefficients indicate the relative risks according to the CHA 2 DS 2 VASc score. Hazard ratios with 95% CIs were derived from Cox models and the proportional hazards assumption was verified with Shoenfeld residuals. Violation of proportional hazards assumptions by time-varying covariates was handled by introducing interaction terms containing the starting time. 22 The predictive accuracy of the CHA 2 DS 2 -VASc score from logistic regression modelling was determined with receiver operating characteristic (ROC) analysis and the resultant areas under the curve (AUCs) in AF and non-AF groups were compared according to the method described by Hanley and McNeil. 23 A P value of less than 0.05 was considered significant. Survival analyses were performed using 'survival', 'survminer' and 'cmprsk', 'prodlim', 'pseudo', 'geepack' and 'pROC' packages and all statistical analyses were done in R (R Core Team 2018; R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; URL: https://www.R-project.org).
Results
The selection of the study population is shown in Supplementary Figure 1 . The population-based prospective cohort (Table 1) included 22,179 middle-aged individuals (mean age 63 AE 7 years; men 39%). The median (interquartile range [IQR]) follow-up period was 15 (3) years. The baseline characteristics of the subjects, divided into two groups according to the presence or absence (prevalent or incident) of AF are reported in Table 1 . The medians (IQR) follow-up period for the entire cohort, AF and no-AF groups were 15 (3), 15 (4) and 15 (3) years, respectively.
The mean CHA 2 DS 2 VASc score was 1.4 in subjects without AF and 1.9 in those with AF. The distribution of the CHA 2 DS 2 VASc score in the two groups is shown in Table 1 .
CHA2DS2VASc score and risk stratification for MACCEs and mortality in subjects with and without AF
During the entire follow-up period, 4406 (20%) subjects had a MACCE, 1899 (8.6%) had a stroke, including 1572 (7.1%) with an ischaemic stroke, 2162 (9.7%) had a coronary event and 5899 (26%) died (8.5% cardiovascular death). The crude incidence rates of considered events at the end of follow-up, according to the CHA 2 DS 2 VASc strata, in the two groups of subjects are reported in Table 2 .
Cumulative incidences, absolute and relative risks of MACCEs and mortality were greater with increasing CHA 2 DS 2 VASc strata in subjects with and without AF (see Supplementary Figure 2 for cumulative incidences of all stroke and coronary events, and Supplementary Figure 3 for cardiovascular and allcause mortality). In particular, the cumulative incidence of ischaemic stroke in the two groups of subjects, according to CHA 2 DS 2 VASc strata, is shown in Figure 1 , panel (a) (subjects without AF) and panel (b) (subjects with AF). Subjects with CHA 2 DS 2 VASc ! 4 without AF had a similar incidence of ischaemic stroke to that of patients with AF and CHA 2 DS 2 VASc 2 (Figure 2(a) ), particularly during the first 10 years of follow-up, with a crude incidence rate of 0.91 (95% CI 0.68-1.19) and 1.13 (95% CI 0.93-1.36) ischaemic strokes per 100 patient-years, respectively ( Figure 2(b) ).
The absolute risks of ischaemic stroke at different time points across different CHA 2 DS 2 VASc strata in both subjects with and without AF are displayed in Supplementary  Figure  4 .
Notably, CHA 2 DS 2 VASc ! 4 in patients without AF carried a 5-year absolute risk of ischaemic stroke similar to CHA 2 DS 2 VASc 2 in patients with AF (4.4% vs. 4.3%, P¼NS).
The CHA 2 DS 2 VASc score in the non-AF population showed a higher predictive accuracy for ischaemic stroke compared with the AF population (AUC 0.60, P < 0.00001 vs. AUC 0.56, P < 0.00001; comparison P < 0.001).
In non-AF patients not on antithrombotic medications (n ¼ 16,820), CHA 2 DS 2 VASc ! 2 was a significant predictor of all-cause death (hazard ratio (HR) 2.58; 95% CI 2.42-2.76), cardiovascular death (HR 3.40; 95% CI 2.98-3.89), ischaemic stroke (HR 2.20; 95% CI 1.92-2.53) and coronary events (HR 1.83; 95% CI 1.63-2.04), regardless of dyslipidaemia and smoking status (see Supplementary Table 1 ). CHA 2 DS 2 VASc score and risk stratification for incident AF Overall, 3094 (13.9%) new AF cases were detected, accounting for an absolute annual incidence of 1.0% (0.99-1.07) per year. The cumulative incidence of AF was greater with increasing CHA 2 DS 2 VASc strata ( Figure 3 ), with an absolute annual incidence of 2.5% per year among individuals with CHA 2 DS 2 VASc ! 4. CHA 2 DS 2 VASc had acceptable discrimination performance (C-statistic 0.61, P < 0.00001) for predicting new-onset AF. The sex-adjusted CHA 2 DS 2 VASc score (calculated by removing consideration for sex category) was found to be significantly more predictive of incident AF in women than in men (AUC 0.67, P < 0.00001 for female sex vs. 0.61, P < 0.00001 for male sex, comparison P < 0.0001).
Multivariable Cox regression analysis revealed CHA 2 DS 2 VASc ! 2 as an independent predictor of 
Discussion
In this study, we have shown that:
. The CHA 2 DS 2 VASc score enables mortality and cardiovascular risk stratification in non-AF middleaged adults; . A CHA 2 DS 2 VASc ! 4 in non-AF individuals is associated with a 5-year absolute risk of ischaemic stroke similar to CHA 2 DS 2 VASc 2 in AF individuals; . A CHA 2 DS 2 VASc ! 4 heralds an ischaemic stroke rate greater than 0.9% per year among non-AF individuals, matching a previously proposed threshold for the safe prescription of non-vitamin K oral anticoagulants (NOACs) in patients with AF;
. The CHA 2 DS 2 VASc score predicts the risk of incident AF in a middle-aged population.
The CHA 2 DS 2 VASc score allows a simple and rapid assessment of thromboembolic risk in patients with non-valvular AF according to the presence of a number of risk factors such as congestive HF, hypertension, age, diabetes, stroke/transient ischaemic attack/thromboembolism, vascular disease and sex category. Most of the individual components of the CHA 2 DS 2 VASc score are established risk factors for stroke, irrespective of the presence of AF. Accordingly, longitudinal prospective studies showed that the CHA 2 DS 2 VASc score is a predictor of ischaemic stroke and death in high-risk patients without known AF, such as patients with HF 12 or coronary heart disease. 11 Moreover, we recently found that the CHA 2 DS 2 VASc score was an independent predictor of ischaemic stroke, coronary events and overall mortality in diabetes patients without AF. 24 Our study confirms and further extends this evidence in a population-based prospective cohort of 22,179 middle-aged individuals, in which CHA 2 DS 2 VASc predicted the risk of ischaemic stroke, any stroke, coronary event, cardiovascular and all-cause mortality, regardless of the AF status, during a particularly long 15-year follow-up.
We observed that in AF-free subjects with a CHA 2 DS 2 VASc ! 4 the risk of ischaemic stroke was similar to AF subjects with CHA 2 DS 2 VASc 2. However, this became less evident after longer (>10 years) follow-up; this is likely to be driven by age difference at baseline, as AF individuals were significantly older than the non-AF population, and with potential for multiple unmeasured confounders. Patients with AF and CHA 2 DS 2 VASc score of 2 or greater are considered to benefit most from anticoagulant therapy. Notably, CHA 2 DS 2 VASc ! 4 in non-AF subjects indicates an ischaemic stroke rate greater than 0.9% per year, which exactly matches the previously proposed 'tipping point' 25 above which the prescription of NOAC therapy is considered to be effective and safe in patients with AF. The pathophysiology of stroke risk in AF is debated, including whether AF is more a risk marker than a risk factor for stroke. 26 In fact, if by one hand AF causes blood stasis in atria, it is also related to a prothrombotic state that contributes to clot formation, probably along with aortic plaques and endothelial injury in cerebral vessels, as epiphenomenon of a systemic high vascular risk condition. The lack of temporality of stroke with device-detected AF is one of the reasons for this uncertainty. 27 Recent data from the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that patients with stable atherosclerotic vascular disease and without known AF treated with a combination of low-dose aspirin (100 mg/ day) and low-dose rivaroxaban (2.5 mg twice daily) had a lower risk of major acute vascular events, including ischaemic stroke, and a lower risk of death, when compared with low-dose aspirin alone. 28 This benefit appears to be particularly striking for subsequent stroke (allegedly atherothrombotic stroke in the majority of such patients without AF). This evidence stands in line with the recent results from the COMMANDER-HF (Cardiovascular Outcome Modification, Measurement AND Evaluation of Rivaroxaban in patients with Heart Failure) trial suggesting a potential additional benefit of rivaroxaban 2.5 mg twice daily in the reduction of stroke among HF patients without prevalent AF. 29 From these data, we may infer that oral anticoagulation exerts a significant protective effect against ischaemic cerebrovascular events, regardless of the AF status. Furthermore, a recent analysis suggested that the availability of NOACs, with a better efficacy and safety profile compared with vitamin-K antagonists lowered the threshold for anticoagulation to a stroke rate level of 0.9% per year in patients with history of AF. 25 Our findings provide a reasonable basis for further research aimed to test the efficacy of NOACs in the primary prevention of ischaemic cerebrovascular events, regardless of AF status and the underlying pathological mechanisms of stroke, namely cardioembolic or atherothrombotic. This is also in line with previous evidence from the WARIS II (Warfarin-Aspirin Reinfarction Study II) trial, in which oral anticoagulation with warfarin was associated with a significant reduction of ischaemic stroke in patients with a recent acute myocardial infarction, regardless of the AF status. 30 Conversely, the phase III NAVIGATE-ESUS (New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs. Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source) study has recently shown no benefit with rivaroxaban at a daily dose of 15 mg, compared with aspirin at a daily dose of 100 mg, for the prevention of stroke recurrence in patients with embolic stroke of undetermined source. 31 Further investigations -based on post-hoc analyses of the aforementioned randomised controlled trials -should probably look at efficacy and safety outcomes of oral anticoagulation in patients without known AF across different CHA 2 DS 2 VASc score strata.
The detection of asymptomatic AF provides an opportunity to prevent ischaemic stroke by instituting appropriate anticoagulation. 32 Opportunistic screening in all patients contacting the health system 65 years of age or older has been adopted in the European Society of Cardiology AF guidelines, 1 but might be more efficient if an older age threshold is chosen or an additional stroke risk factor is selected. 33 Despite the bulk of investigations aimed to conceive the most appropriate tool and setting for AF screening, also including the use of cardiac implanted electronic devices to detect atrial high-rate episodes, little is known about who would benefit the most from a widespread AF screening programme, and which screening technique and risk stratification tool would provide the optimal diagnostic yield. 26 The CHA 2 DS 2 VASc score, a simple, practical and user-friendly scoring scheme which was initially used for stroke risk discrimination among patients with AF, has gained attention for predicting different cardiovascular outcomes in different populations. Importantly, a retrospective analysis from a large nationwide Taiwanese dataset of nearly 70,000 patients with type 2 diabetes mellitus reported on the predictive ability of the CHA 2 DS 2 VASc score for stratifying the risk of incident AF. 34 Interestingly, the CHA 2 DS 2 VASc score, a risk scoring system excluding consideration for sex category from CHA 2 DS 2 VASc, revealed significantly higher prognostic yield for incident AF in women than in men. While the exact mechanism responsible for the reported sex-related difference in AF remains inadequately understood, differences in AF incidence observed by sex may be explained by sex-specific distribution of risk factors and by differential associations of classic risk factors. 35 Compared with the strategies for 'retrospective' identification of AF and thromboembolic risk prevention, the 'prospective' risk analysis for new-onset AF has gained hitherto relatively little attention. Our data strengthen current evidence about the concurrent ability of the CHA 2 DS 2 VASc score for predicting newonset AF and stratifying the risk of stroke, coronary events, cardiovascular mortality and all-cause mortality in non-AF individuals. This may prompt the idea of rethinking current strategies of cardiovascular risk prediction and consider AF itself as an additive risk factor 36 -on top of other CHA 2 DS 2 VASc components -for stroke and major cardiovascular events. Moreover, the evidence of a CHADSVASC !4 cutoff attaining the rate of ischaemic events matching established safety threshold for oral anticoagulation may pave the way for a rethinking of current dogmas about stroke prevention schemes in non-AF populations.
Strengths and limitations
The principal strengths of this study are the large study population, the extensive follow-up time, as well as the reliability of the prospective data collection protocol of our registries.
The main limitation of this study is the lack of prospective reappraisal of CHA 2 DS 2 VASc risk factors and assessment of oral antithrombotic therapy during follow-up, as well as the lack of important pieces of information 37 such as AF classification, bleeding events and the precise indications for baseline antithrombotic treatment in patients without AF.
Conclusions
The CHA 2 DS 2 VASc score is a sensitive tool for the prediction of new-onset AF and risk stratification of MACCEs in individuals both with and without prevalent or incident AF. The annual rate of ischaemic stroke in CHA 2 DS 2 VASc ! 4 patients without AF was above 0.9% per year, exceeding the current advised threshold for the safe prescription of NOACs in patients with atrial fibrillation. The exceedingly high risk of ischaemic stroke observed in CHA 2 DS 2 VASc ! 4 subjects without AF may provide guidance for future randomised clinical trial to test the safety and efficacy of direct oral anticoagulants for the primary prevention of atherothrombotic events.
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